908 Devices Stock Earnings Reports

908 Devices reported Q1 2026 revenue of $13.4M, up 14% year-over-year, driven primarily by handheld product and service revenue (+16% YoY). The company shipped 167 devices in the quarter, bringing the installed base to 3,903. Gross margin improved to 51% (adjusted gross margin 57%), and adjusted EBITDA loss narrowed to -$2.5M (a 45% improvement vs. prior year). Cash, cash equivalents and marketable securities totaled $111.7M with no debt, and operating cash burn was modest (~$1.2M) for the quarter. Management announced the acquisition of NIRLAB AG for an upfront $15M ( $13M cash, $2M equity) with up to $8M of additional equity contingent on performance; NIRLAB is expected to contribute approximately $2.5M revenue for the remainder of 2026, grow to >$5M in 2027, and be roughly a $1M adjusted EBITDA headwind in 2026 but accretive/profitable in 2027. Updated full-year 2026 guidance: revenue $67M–$70M (up $2.5M), handheld revenue $62M–$64M, OEM/funded partnerships ~$3M, AVCAD program $2M–$3M (likely H2). Key strategic points: expansion of recurring revenue and software strategy (Team Leader + NIRLAB subscriptions), broadened handheld portfolio (MX908, VipIR, FTIR products, NIRLAB near-IR device), strengthened U.S. state & local momentum (≈50% of Q1 revenue; consistent run-rate demand), and continued focus on margin improvement and disciplined cost structure. Risks/near-term headwinds include a ~ $1M adjusted EBITDA drag from the NIRLAB acquisition in 2026, contingent consideration revaluations (Q1 included a $3.9M noncash increase), and execution risk in scaling NIRLAB into the U.S. market.